Pooled week 48 safety and efficacy results from the ECHO and THRIVE phase III trials comparing TMC278 vs EFV in treatment-naive, HIV-1-infected patients

ABSTRACT:

SUBMITTER: Cohen C 

PROVIDER: S-EPMC3112863 | biostudies-literature | 2010 Jan

REPOSITORIES: biostudies-literature